News Sentiment

LXEO sentiment intelligence

Lexeo Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 52 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.82 Week of 10 Jul 2026
Weighted tone 52/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 55

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

+2.8% over one week, +10.3% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple

Market Reaction

Balanced read

61/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction 2.8% Price confirming higher
Trend fit Trend inactive 10.3% over four weeks
Fair value -44.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 46
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 55
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 7
GlobeNewswire 6
TradingView 4
Simply Wall Street 3
Investing.com Canada 3
simplywall.st 3
Investing.com 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 19
Analyst action 3
Regulatory and legal 2
Deals and strategy 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Market source Direct company coverage

What Makes Lexeo Therapeutics (LXEO) One of The Best Stocks Under $10 That Could Triple

Lexeo Therapeutics (LXEO) is highlighted as a top stock under $10 with the potential to triple, following the finalization of its critical trial protocol for SUNRISE-FA 2 and statistical analysis plan for LX2006, a gene-based therapy for Friedreich's ataxia cardiomyopathy. Despit

Tone
Positive 65/100
Event
Market update
Published
15 Jul 2026 15:42
Source
Market source
Simply Wall Street Direct company coverage

Lexeo Therapeutics (Nasdaq:LXEO) - Stock Analysis

Lexeo Therapeutics (LXEO), a clinical-stage genetic medicine company, is currently unprofitable and trading below its estimated fair value with projected revenue growth of 65.61% per year. The company's primary focus is LX2006 for Friedreich's ataxia (FA) cardiomyopathy, which ha

Tone
Positive 66/100
Event
Earnings
Published
10 Jul 2026 06:40
Source
Simply Wall Street
Simply Wall Street Direct company coverage

Lexeo Therapeutics (NasdaqGM:LXEO) Stock Forecast & Analyst Predictions

Lexeo Therapeutics (NasdaqGM:LXEO) is projected to experience significant growth in earnings and revenue, with analysts forecasting 48.9% and 65.6% increases per annum, respectively. The company is advancing its gene therapy LX2006 for Friedreich's ataxia cardiomyopathy, with piv

Tone
Positive 74/100
Event
Earnings
Published
08 Jul 2026 07:41
Source
Simply Wall Street
Finviz Direct company coverage

LXEO - Lexeo Therapeutics Inc Dividends

This page provides a detailed financial overview of Lexeo Therapeutics Inc. (LXEO), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, insider ownership, institutional ownersh

Tone
Neutral 50/100
Event
Earnings
Published
05 Jul 2026 04:40
Source
Finviz
富途牛牛 Direct company coverage

Have Lexeo Therapeutics Insiders Been Selling Stock?

The article "Have Lexeo Therapeutics Insiders Been Selling Stock?" provides an analysis of insider trading activity at Lexeo Therapeutics. It reviews recent transactions to determine if company insiders have been buying or selling shares. The article aims to shed light on how tho

Tone
Negative 40/100
Event
Market update
Published
04 Jul 2026 06:10
Source
富途牛牛
Simply Wall Street Direct company coverage

Have Insiders Sold Lexeo Therapeutics Shares Recently?

Lexeo Therapeutics' Chief Medical Officer, Narinder Bhalla, recently sold US$99k worth of stock, reducing their holding by 21%. This follows a larger sale by the CEO & Director, R. Townsend, for US$117k in the last year, though that transaction was at a higher price than current

Tone
Negative 34/100
Event
Market update
Published
03 Jul 2026 11:40
Source
Simply Wall Street
Stock Titan Direct company coverage

[144] Lexeo Therapeutics, Inc. SEC Filing

This article reports on a Form 144 SEC filing by Lexeo Therapeutics, Inc. (LXEO) on July 1, 2026. The filing indicates a proposed sale of 22,306 shares of common stock with an aggregate market value of $98,683.97, acquired on June 29, 2026, through restricted stock vesting. The s

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 18:11
Source
Stock Titan
Insider Monkey Direct company coverage

Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update?

JPMorgan recently lowered its price target for Lexeo Therapeutics, Inc. (LXEO) to $9 from $12 but maintained an Overweight rating, based on an updated valuation model. Lexeo also announced the completion of the SUNRISE-FA 2 pivotal trial protocol for its gene therapy candidate LX

Tone
Positive 64/100
Event
Analyst action
Published
02 Jul 2026 16:06
Source
Insider Monkey
Stock Titan Direct company coverage

Lexeo Therapeutics (LXEO) COO reports stock award and small tax-related sale

Lexeo Therapeutics' Chief Operating Officer, Jose Manuel Otero, reported receiving a stock grant of 12,060 shares on June 29 and subsequently selling 4,666 shares on July 1 to cover tax obligations related to the vesting of performance Restricted Stock Units (RSUs). After these t

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 03:09
Source
Stock Titan
Investing.com Canada Direct company coverage

Lexeo Therapeutics CMO sells $98,592 in shares By Investing.com

Lexeo Therapeutics' Chief Medical Officer, Narinder Pal Bhalla, sold 22,306 shares of common stock for $98,592 to cover tax obligations from Restricted Stock Units. This transaction occurred after acquiring 55,000 shares at $0.00 and leaves him with 82,194 shares. The company is

Tone
Negative 41/100
Event
Market update
Published
02 Jul 2026 00:09
Source
Investing.com Canada
Investing.com Direct company coverage

Lexeo Therapeutics CMO sells $98,592 in shares

Narinder Pal Bhalla, CMO of Lexeo Therapeutics (NASDAQ:LXEO), sold 22,306 shares totaling $98,592 to cover tax obligations from RSU releases. This transaction follows an acquisition of 55,000 shares on June 29, 2026, and leaves Mr. Bhalla with 82,194 shares. The company is active

Tone
Positive 60/100
Event
Deals and strategy
Published
01 Jul 2026 23:15
Source
Investing.com
Investing.com Direct company coverage

Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock

Lexeo Therapeutics COO Jose Manuel Otero sold 4,666 shares of LXEO stock for $20,903 to cover tax obligations. The stock is currently trading at $4.45, down 55% over the past six months. The company recently published Phase I/II study results for its gene therapy LX2006 for Fried

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 23:15
Source
Investing.com
Stock Titan Direct company coverage

RSU grant and tax-cover share sale by Lexeo (LXEO) chief financial officer

Lexeo Therapeutics' Chief Financial Officer, Louis Edward Tamayo, reported an award of 12,000 shares of common stock and subsequently sold 4,641 shares at a weighted average price of $4.49 each. This sale was explicitly made to cover tax obligations arising from the vesting of pe

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

Lexeo Therapeutics (LXEO) CEO logs RSU grant and tax-driven share sale

Richard Nolan Townsend, CEO of Lexeo Therapeutics, reported two equity transactions: a grant of 67,000 shares on June 29, 2026, and the sale of 25,947 shares on July 1, 2026, at a weighted average price of $4.48. The sale was specifically to cover tax obligations from vested Rest

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:09
Source
Stock Titan
Stock Titan Direct company coverage

Lexeo Therapeutics (LXEO) CMO awarded 55K shares and sells 22K to cover RSU taxes

Lexeo Therapeutics' Chief Medical Officer, Narinder Pal Bhalla, received a grant of 55,000 common shares on June 29, 2026, as part of his compensation. To cover tax obligations related to the release of performance Restricted Stock Units (RSUs), Bhalla subsequently sold 22,306 sh

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:09
Source
Stock Titan
Investing.com Canada Direct company coverage

Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock By Investing.com

Lexeo Therapeutics COO Jose Manuel Otero sold 4,666 shares of LXEO stock for $20,903 to cover tax obligations from vested RSUs. This transaction occurred on July 1, 2026, with shares sold at a weighted average price of $4.48. Otero still directly holds 137,482 shares, including R

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 23:09
Source
Investing.com Canada
Investing.com Canada Direct company coverage

Form 4 Lexeo Therapeutics Inc For: 1 July By Investing.com

This article reports on the filing of Form 4 for Lexeo Therapeutics Inc. on July 1st. It also includes general market data, popular news headlines from Investing.com, and various market indices and commodity prices. The content primarily focuses on financial markets and company n

Tone
Neutral 50/100
Event
Macro sensitivity
Published
01 Jul 2026 23:09
Source
Investing.com Canada
Stock Titan Direct company coverage

LXEO (NASDAQ) Form 144: Proposed resale of 4,666 vested shares via Fidelity

Lexeo Therapeutics, Inc. (LXEO) has filed a Form 144 notice indicating a proposed resale of 4,666 common shares through Fidelity Brokerage Services LLC. These shares are linked to a restricted stock vesting event that occurred on June 29, 2026, as compensation. The filing is proc

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:15
Source
Stock Titan
Stock Titan Direct company coverage

Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70

Lexeo Therapeutics director Brenda Cooperstone was granted 35,000 stock options with an exercise price of $4.70 per share, expiring on June 24, 2036. The options will vest one year after the grant date or at the next annual meeting, provided she maintains continuous service. This

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 02:11
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Lexeo Therapeutics Inc For: 29 June By Investing.com

This article from Investing.com reports on a Form 4 filing for Lexeo Therapeutics Inc., indicating insider trading activity. The filing pertains to actions taken on June 29 and is a standard regulatory disclosure for public companies. The article provides only this brief detail w

Tone
Neutral 50/100
Event
Regulatory and legal
Published
29 Jun 2026 21:46
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Lexeo Therapeutics (LXEO) director awarded options on 35,000 shares at $4.70

Lexeo Therapeutics director Steven Altschuler was granted options for 35,000 shares of common stock at an exercise price of $4.70 per share, expiring on June 24, 2036. The options will vest either one year after the grant date or at the next annual stockholders' meeting, provided

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 21:11
Source
Stock Titan
Stock Titan Direct company coverage

Lexeo Therapeutics (NASDAQ: LXEO) investors approve directors and ratify KPMG auditor

Lexeo Therapeutics, Inc. (NASDAQ: LXEO) shareholders approved the election of three Class III directors—R. Nolan Townsend, Brenda Cooperstone, M.D., and Paula HJ Cholmondeley—to serve until the 2029 annual meeting. Additionally, stockholders ratified the appointment of KPMG LLP a

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Lexeo Therapeutics (LXEO) director receives grant of 35,000 stock options at $4.70

Lexeo Therapeutics, Inc. director Paula H. Cholmondeley was granted 35,000 stock options at an exercise price of $4.70 per share, expiring on June 24, 2036. The options will vest on the earlier of one year after the grant date or the next annual stockholders' meeting, subject to

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

Lexeo Therapeutics (LXEO) director awarded 35,000 stock options at $4.70 strike

Lexeo Therapeutics director Reinaldo M. Diaz was granted 35,000 stock options at an exercise price of $4.70 per share as equity compensation. These options will vest on the earlier of one year from the grant date or the next annual stockholders' meeting, conditional on his contin

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 06:40
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Lexeo Therapeutics, Inc. – NASDAQ:LXEO

This article displays the "Price to sales forward" metric for Lexeo Therapeutics, Inc. under the NASDAQ:LXEO ticker. It presents a financial overview of the company on the TradingView platform, showing the period, value, change, and percentage change for this specific financial i

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 05:39
Source
TradingView